Valuation: Axsome Therapeutics, Inc.

Market Cap 11.43B 9.8B 9.15B 8.4B 15.79B 1,092B 16.06B 108B 42.3B 548B 42.92B 41.98B 1,812B P/E 2026 *
-81.9x
P/E 2027 * 46.8x
Enterprise Value 11.27B 9.67B 9.03B 8.28B 15.58B 1,077B 15.84B 107B 41.72B 540B 42.33B 41.41B 1,787B EV / Sales 2026 *
11.6x
EV / Sales 2027 * 7.04x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day+1.16%
1 week+1.13%
Current month+0.10%
1 month-5.13%
3 months-4.05%
6 months+18.11%
Current year+19.47%
1 week 208.95
Extreme 208.95
222.46
1 month 206.94
Extreme 206.94
245.5
Current year 152.28
Extreme 152.28
260.19
1 year 111.54
Extreme 111.545
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.7
Extreme 19.7
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
8/6/26 Fiscal year

Chief Executive Officer

13,980 0.0272%
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/5/26 Free

Director

1,721 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%+1.13%+96.35%+208.28% 11.3B
+3.78%+5.50%+46.51%+3.50% 80.91B
+2.80%+23.76%-24.02%-35.79% 53.62B
+0.85%-4.04%-2.31%+30.25% 50.13B
+0.23%-3.71%+11.44%+170.56% 47.97B
+4.24%+8.67%+63.02%-15.16% 31.41B
+176.97%+187.90%+520.79%+71.60% 25.14B
+4.05%+6.11%+51.28%+100.61% 25.03B
+1.66%+2.83%-3.58%+212.40% 21.45B
+0.22%+5.48%+65.69%+127.79% 16.93B
Average +1.55%+20.79%+82.52%+87.40% 36.39B
Weighted average by Cap. +1.95%+15.99%+58.77%+57.65%

Financials

2026 *2027 *
Net sales 971M 833M 778M 714M 1.34B 92.81B 1.36B 9.18B 3.59B 46.55B 3.65B 3.57B 154B 1.56B 1.34B 1.25B 1.15B 2.16B 149B 2.19B 14.76B 5.78B 74.88B 5.87B 5.74B 248B
Net income -140M -120M -112M -103M -193M -13.35B -196M -1.32B -517M -6.69B -524M -513M -22.13B 259M 222M 207M 190M 358M 24.73B 363M 2.45B 958M 12.4B 971M 950M 41.01B
Net Debt -156M -134M -125M -115M -216M -14.96B -220M -1.48B -579M -7.5B -588M -575M -24.8B -435M -373M -349M -320M -602M -41.61B -612M -4.11B -1.61B -20.87B -1.63B -1.6B -69B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
26-08-19 $218.20 +1.16% 572,113
26-08-18 $215.69 -0.27% 506,353
26-08-17 $216.27 +1.22% 511,870
26-08-14 $213.67 -0.00% 476,327
26-08-13 $213.68 -0.46% 705,315
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
218.20USD
Average target price
285.42USD
Spread / Average Target
+30.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock